Hospital
Aurora Medical Center Grafton, LLC
Aurora Medical Center Grafton, LLC was paid $7.35M by Medicaid between Jan 2018 and Dec 2024, across 190 billing codes. Its largest line is 97110, Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion — 16% of everything it billed.
33Billing provider infoAURORA MEDICAL CENTER GRAFTON, LLC
GRAFTON, WI 53024
GRAFTON, WI 53024
33aNPI1265740195assigned 09/14/2010
33bProvider typeGeneral Acute Care Hospital
28Total paid$7.35M
24GClaims393,832
24DCodes billed190
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Wisconsin
Rank by total paid#19 of 60
Median peer was paid$2.90M
This provider vs. median2.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Auditor's notes
Automated statistical signals. Not evidence of fraud — how these are computed.
Entity ProliferationAuthorized official RICHARDSON, KARA controls 20+ related entities in our dataset. Read more
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 41,721 | $813K | |
| 2019 | 46,177 | $856K | |
| 2020 | 45,197 | $840K | |
| 2021 | 66,186 | $1.19M | |
| 2022 | 66,504 | $1.19M | |
| 2023 | 73,384 | $1.37M | |
| 2024incomplete | 54,663 | $1.08M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 97110 | Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion | 16% | 36,597 | 14,219 | $1.18M |
| 96361 | Intravenous infusion, hydration; each additional hour | 9.3% | 5,306 | 4,341 | $684K |
| 97140 | Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) | 6.4% | 21,937 | 8,985 | $472K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 6.4% | 9,008 | 7,973 | $469K |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 6.1% | 7,638 | 6,895 | $448K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 4.7% | 6,658 | 5,876 | $346K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | 4.2% | 12,118 | 7,298 | $307K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | 3.2% | 1,284 | 1,180 | $235K |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | 2.8% | 2,383 | 2,119 | $208K |
| 80053 | Comprehensive metabolic panel | 2.8% | 13,490 | 10,541 | $204K |
| 97112 | Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination | 2.7% | 7,461 | 3,894 | $199K |
| 97162 | 2.4% | 4,479 | 4,263 | $173K |
178 more codes
| 70450 | Computed tomography, head or brain; without contrast material | 2.4% | 2,769 | $173K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 2.3% | 2,270 | $172K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | 2.1% | 2,132 | $158K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.4% | 1,661 | $105K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 1.3% | 17,196 | $97K |
| 97161 | 1.3% | 2,383 | $96K | |
| 45380 | Colonoscopy, flexible; with biopsy, single or multiple | 1.1% | 526 | $81K |
| 80048 | Basic metabolic panel (calcium, ionized) | 1.1% | 5,523 | $78K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.0% | 1,445 | $76K |
| 96366 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour | 1.0% | 704 | $74K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,805 | $72K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 2,162 | $69K |
| 84484 | <1% | 5,467 | $51K | |
| 82962 | <1% | 7,202 | $50K | |
| 74176 | Computed tomography, abdomen and pelvis; without contrast material | <1% | 682 | $50K |
| 0241U | Neonatal screening for hereditary disorders, genomic sequence analysis panel | <1% | 1,229 | $48K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | <1% | 454 | $45K |
| G0378 | Hospital observation service, per hour | <1% | 2,688 | $44K |
| 97116 | <1% | 2,578 | $37K | |
| 83735 | <1% | 7,032 | $36K | |
| 81025 | <1% | 3,643 | $35K | |
| 97035 | <1% | 2,960 | $32K | |
| 71275 | Computed tomographic angiography, chest, with contrast material | <1% | 359 | $32K |
| 92507 | Treatment of speech, language, voice, communication, and/or auditory processing disorder | <1% | 620 | $31K |
| 82077 | <1% | 1,408 | $31K | |
| 83880 | <1% | 1,103 | $30K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 485 | $29K |
| G0283 | Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care | <1% | 2,213 | $29K |
| 83690 | <1% | 4,672 | $25K | |
| 64721 | <1% | 87 | $22K | |
| 97165 | <1% | 619 | $20K | |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | <1% | 114 | $20K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 69 | $20K |
| 84145 | <1% | 1,033 | $19K | |
| 70553 | Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences | <1% | 170 | $18K |
| 45385 | Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) | <1% | 78 | $17K |
| 84703 | <1% | 1,822 | $16K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 1,866 | $16K |
| 83605 | <1% | 1,761 | $16K | |
| 97016 | <1% | 983 | $15K | |
| 0240U | <1% | 559 | $15K | |
| 97166 | <1% | 448 | $15K | |
| 97163 | <1% | 456 | $14K | |
| 81001 | <1% | 4,177 | $14K | |
| 97535 | Self-care/home management training, each 15 minutes | <1% | 1,036 | $12K |
| 85610 | <1% | 3,920 | $12K | |
| 87040 | <1% | 1,029 | $11K | |
| M0243 | Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring | <1% | 48 | $11K |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 469 | $11K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 897 | $11K |
| 86850 | <1% | 837 | $10K | |
| 81003 | <1% | 2,313 | $10K | |
| 76705 | Ultrasound, abdominal, real time with image documentation; limited | <1% | 375 | $10K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 121 | $10K |
| 85027 | <1% | 2,142 | $9K | |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 200 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 165 | $9K |
| 80143 | <1% | 780 | $9K | |
| 85730 | <1% | 1,919 | $8K | |
| 85379 | <1% | 1,043 | $8K | |
| 80179 | <1% | 726 | $8K | |
| 93356 | <1% | 82 | $8K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 168 | $8K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 225 | $7K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 5,490 | $6K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 3,164 | $5K |
| 86900 | <1% | 951 | $5K | |
| 97597 | <1% | 97 | $5K | |
| 93017 | <1% | 176 | $4K | |
| 76830 | Ultrasound, transvaginal | <1% | 157 | $4K |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 270 | $4K |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 270 | $4K |
| 87077 | <1% | 482 | $4K | |
| 93975 | <1% | 101 | $4K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 541 | $4K |
| 93971 | <1% | 172 | $3K | |
| 71260 | Computed tomography, thorax, diagnostic; with contrast material | <1% | 31 | $3K |
| 86901 | <1% | 950 | $2K | |
| 72148 | Magnetic resonance imaging, lumbar spine; without contrast material | <1% | 34 | $2K |
| 87070 | <1% | 221 | $2K | |
| 71045 | Radiologic examination, chest; single view | <1% | 5,360 | $2K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 3,743 | $2K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 26 | $2K |
| 86140 | <1% | 386 | $1K | |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 23 | $1K |
| Q0243 | Injection, casirivimab and imdevimab, 2400 mg | <1% | 35 | $1K |
| 87205 | <1% | 317 | $1K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 9,661 | $993.03 |
| 87186 | <1% | 175 | $934.38 | |
| 85014 | <1% | 230 | $898.53 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 120 | $825.97 |
| 80047 | <1% | 12 | $771.12 | |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 4,989 | $574.76 |
| 82565 | <1% | 84 | $520.31 | |
| 82550 | <1% | 120 | $487.22 | |
| 76536 | <1% | 14 | $440.01 | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 14 | $435.85 |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 14 | $435.85 |
| 71250 | <1% | 29 | $426.15 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 11,405 | $315.16 |
| 80061 | Lipid panel | <1% | 44 | $307.35 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 43 | $300.00 |
| 85652 | <1% | 139 | $275.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | <1% | 9,191 | $274.51 |
| 77002 | <1% | 12 | $265.28 | |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 3,691 | $251.86 |
| 94060 | <1% | 13 | $218.84 | |
| 36000 | <1% | 228 | $202.06 | |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 4,903 | $198.55 |
| J2704 | Injection, propofol, 10 mg | <1% | 14,020 | $187.60 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,501 | $177.77 |
| 82607 | <1% | 14 | $174.19 | |
| 82746 | <1% | 15 | $169.83 | |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 14 | $154.78 |
| 94729 | <1% | 13 | $122.25 | |
| 89051 | <1% | 24 | $118.56 | |
| 94726 | <1% | 13 | $109.40 | |
| 74018 | <1% | 41 | $108.93 | |
| 88307 | <1% | 76 | $95.92 | |
| C1769 | Guide wire | <1% | 1,320 | $73.67 |
| 87210 | <1% | 13 | $66.72 | |
| 96376 | <1% | 2,426 | $66.26 | |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | <1% | 120 | $57.87 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 9,170 | $49.50 |
| J0665 | Injection, bupivicaine, not otherwise specified, 0.5 mg | <1% | 597 | $46.48 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 5,287 | $41.30 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 4,646 | $19.45 |
| C1894 | Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser | <1% | 670 | $18.22 |
| A9585 | Injection, gadobutrol, 0.1 ml | <1% | 1,338 | $9.46 |
| 72100 | <1% | 14 | $9.36 | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 212 | $8.90 |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 5,190 | $5.69 |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 1,753 | $3.15 |
| 36415 | Collection of venous blood by venipuncture | <1% | 3,181 | $2.04 |
| J1815 | Injection, insulin, per 5 units | <1% | 966 | $0.74 |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | <1% | 1,045 | $0.42 |
| J2060 | Injection, lorazepam, 2 mg | <1% | 1,265 | $0.29 |
| J2469 | Injection, palonosetron hcl, 25 mcg | <1% | 540 | $0.27 |
| G1004 | Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program | 0% | 1,072 | $0.00 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | 0% | 1,076 | $0.00 |
| J1650 | Injection, enoxaparin sodium, 10 mg | 0% | 1,334 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 946 | $0.00 |
| J1644 | Injection, heparin sodium, per 1000 units | 0% | 1,759 | $0.00 |
| C9113 | Injection, pantoprazole sodium, per vial | 0% | 240 | $0.00 |
| C1713 | Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) | 0% | 1,265 | $0.00 |
| G8979 | Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting | 0% | 296 | $0.00 |
| Q9957 | Injection, perflutren lipid microspheres, per ml | 0% | 110 | $0.00 |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | 0% | 115 | $0.00 |
| J3475 | Injection, magnesium sulfate, per 500 mg | 0% | 545 | $0.00 |
| A4565 | Slings | 0% | 106 | $0.00 |
| G8978 | Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals | 0% | 254 | $0.00 |
| J3370 | Injection, vancomycin hcl, 500 mg | 0% | 86 | $0.00 |
| J1171 | Injection, hydromorphone, 0.1 mg | 0% | 58 | $0.00 |
| 73630 | 0% | 15 | $0.00 | |
| C1776 | Joint device (implantable) | 0% | 28 | $0.00 |
| A6212 | Foam dressing, wound cover, sterile, pad size 16 sq. in. or less, with any size adhesive border, each dressing | 0% | 29 | $0.00 |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 0% | 26 | $0.00 |
| 73030 | 0% | 12 | $0.00 | |
| J0780 | Injection, prochlorperazine, up to 10 mg | 0% | 18 | $0.00 |
| J2370 | Injection, phenylephrine hcl, up to 1 ml | 0% | 471 | $0.00 |
| J2765 | Injection, metoclopramide hcl, up to 10 mg | 0% | 889 | $0.00 |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 0% | 697 | $0.00 |
| J0131 | Injection, acetaminophen, not otherwise specified,10 mg | 0% | 464 | $0.00 |
| J2795 | Injection, ropivacaine hydrochloride, 1 mg | 0% | 1,944 | $0.00 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | 0% | 4,719 | $0.00 |
| J2785 | Injection, regadenoson, 0.1 mg | 0% | 55 | $0.00 |
| J0360 | Injection, hydralazine hcl, up to 20 mg | 0% | 193 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 434 | $0.00 |
| J7999 | Compounded drug, not otherwise classified | 0% | 135 | $0.00 |
| J7512 | Prednisone, immediate release or delayed release, oral, 1 mg | 0% | 51 | $0.00 |
| J1920 | Injection, labetalol hydrochloride, 5 mg | 0% | 31 | $0.00 |
| J0173 | Injection, epinephrine (belcher), not therapeutically equivalent to j0171, 0.1 mg | 0% | 59 | $0.00 |
| J3360 | Injection, diazepam, up to 5 mg | 0% | 13 | $0.00 |
| J1642 | Injection, heparin sodium, (heparin lock flush), per 10 units | 0% | 14 | $0.00 |
| Q9965 | Low osmolar contrast material, 100-199 mg/ml iodine concentration, per ml | 0% | 93 | $0.00 |
| 88304 | 0% | 71 | $0.00 | |
| J0330 | Injection, succinylcholine chloride, up to 20 mg | 0% | 15 | $0.00 |
| A6222 | Gauze, impregnated with other than water, normal saline, or hydrogel, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialRICHARDSON, KARA (VP MANAGED HEALTH)
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.